{"id":313876,"date":"2025-11-28T07:42:12","date_gmt":"2025-11-28T07:42:12","guid":{"rendered":"https:\/\/www.newsbeep.com\/au\/313876\/"},"modified":"2025-11-28T07:42:12","modified_gmt":"2025-11-28T07:42:12","slug":"novo-nordisk-or-pfizer-which-healthcare-giant-is-the-better-bet","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/au\/313876\/","title":{"rendered":"Novo Nordisk or Pfizer: Which Healthcare Giant Is the Better Bet?"},"content":{"rendered":"

Novo Nordisk\u00a0NVO<\/a> and Pfizer PFE<\/a> are pharmaceutical giants based in Denmark and the United States, respectively, with strong leadership positions in distinct therapeutic areas. NVO is widely recognized as the market leader in the GLP-1 space, marketing its semaglutide drugs under brand names Ozempic (pre-filled pen) and Rybelsus (oral tablet) for type II diabetes (T2D), and Wegovy (injection) for chronic weight management.<\/p>\n

Pfizer, traditionally strongest in oncology, where the segment accounts for nearly a third of its revenues, also maintains solid depth across inflammation, immunology, rare diseases and vaccines. But a recent strategic shift has brought Pfizer into much closer comparison with Novo Nordisk, as the company re-entered the obesity arena after winning a high-profile bidding war against NVO for the acquisition of Metsera, ultimately sealing the deal in mid-November.<\/p>\n

The Metsera acquisition puts Pfizer back on the offensive in the lucrative obesity space after it scrapped the development of danuglipron,\u00a0a weight-loss pill, earlier this year. With both companies now positioned in obesity \u2014 one defending its lead and the other mounting a fresh challenge \u2014 NVO and PFE have become increasingly comparable from an investment standpoint.<\/p>\n

But which stock presents a better investment opportunity right now? Let\u2019s dive into their fundamentals, growth outlook and potential challenges to make a well-informed comparison.<\/p>\n

The Case for NVO<\/p>\n

Novo Nordisk has achieved tremendous success in the cardiometabolic treatment space, all thanks to its semaglutide medicines, Ozempic, Rybelsus and Wegovy, which are its primary top-line drivers. As of September 2025-end, Novo Nordisk remained the market leader with a total GLP-1 volume market share of 59% globally, across diabetes and obesity care.<\/p>\n

NVO has been investing heavily to expand its manufacturing capacity as part of its strategic move to strengthen its diabetes and obesity care market leadership for its GLP-1 products.<\/p>\n

Novo Nordisk is pursuing new indications for its semaglutide drugs, including cardiovascular (CV) and other indications. Recently, Rybelsus became\u00a0the first oral therapy approved in the United States<\/a>\u00a0to lower the risk of major adverse CV events in high-risk T2D patients, regardless of prior CV history. Wegovy\u2019s label includes cardiovascular, HFpEF and osteoarthritis indications, while Ozempic remains the only GLP-1 approved to slow kidney disease and reduce CV death in patients with diabetes.<\/p>\n

The FDA is also reviewing NVO\u2019s application for a 25 mg oral semaglutide (Wegovy pill) for obesity and CV disease, with a decision expected by year-end. Higher-dose Wegovy injections are also under review in the United States and EU, and the company is seeking to expand Ozempic\u2019s label to include peripheral artery disease.<\/p>\n

Novo Nordisk is advancing its next-generation obesity pipeline. Its most advanced program, CagriSema, a follow-up drug to Wegovy, met study endpoints but underperformed on weight loss outcomes in late-stage studies. Meanwhile, its mid-stage asset, amycretin, recently showed strong weight-loss efficacy in a phase II study and is slated to enter phase III in 2026. The company has bolstered its pipeline through several major collaborations and acquisition deals.<\/p>\n

Beyond GLP-1s, NVO is building its Rare Disease franchise, advancing Mim8 in hemophilia A, and securing both EU and U.S. approvals for Alhemo to treat hemophilia A and B, with or without inhibitors. Meanwhile, the FDA has granted accelerated approval for Wegovy in treating MASH with fibrosis. Novo Nordisk and rival Eli Lilly LLY<\/a> signed a drug pricing agreement with the Trump administration earlier this month, offering to cut prices of their respective GLP-1 medicines for a three-year exemption from tariffs on pharmaceutical imports.<\/p>\n

However, Novo Nordisk has been facing rising competitive and operational headwinds. Weaker-than-expected sales of Ozempic and Wegovy led to disappointing third-quarter results<\/a>, amid intensifying competition from Eli Lilly\u2019s tirzepatide-based drugs, Mounjaro (T2D) and Zepbound (obesity), along with rising use of compounded semaglutide in the United States \u2014 factors that also drove its July guidance cut. Following third-quarter results, Novo Nordisk further trimmed its 2025 sales and operating profit outlook due to pricing pressure, intensifying GLP-1 competition and foreign exchange headwinds. To streamline operations, NVO also announced a restructuring program, including job cuts, aimed at delivering about DKK 8 billion in annual savings by 2026.<\/p>\n

The Case for PFE<\/p>\n

Pfizer is one of the largest and most successful drugmakers in oncology. The addition of Seagen in 2023 strengthened its position in oncology. Its oncology revenues have risen 7% year to date, driven by drugs like Xtandi, Lorbrena, the Braftovi-Mektovi combination and Padcev.<\/p>\n

Pfizer\u2019s non-COVID operational revenues are improving, driven by its key in-line products like Vyndaqel, Padcev and Eliquis, new launches and newly acquired products like Nurtec and those from Seagen. Pfizer’s recently launched and acquired products rose approximately 9% operationally in the nine months of 2025, with the momentum expected to continue.<\/p>\n

Continued growth of Pfizer\u2019s diversified portfolio of drugs, particularly oncology, should support top-line growth in 2026.<\/p>\n

Its significant cost reduction initiatives and efforts to improve R&D productivity measures are also driving profit growth. Pfizer expects cost cuts and internal restructuring to deliver savings of $7.7 billion by the end of 2027. The company\u2019s dividend yield stands at around 7%, which is impressive.<\/p>\n

Pfizer\u2019s new products\/late-stage pipeline candidates and newly acquired products position it strongly for operational growth in 2025 and beyond. It expects the 2025 to 2030 revenue CAGR to be approximately 6%.<\/p>\n

Pfizer is also trying to expand its pipeline through acquisitions. Following a heated battle, with PFE and NVO raising their offer prices for Metsera\u00a0back and forth, Pfizer eventually acquired Metsera, a New York-based biotech, for around $10 billion. Metsera is developing innovative therapies to treat obesity and cardiometabolic diseases, which are expected to generate billions of dollars in peak sales. The acquisition has added a portfolio of promising, clinical-stage incretin and amylin programs to Pfizer\u2019s pipeline. Metsera\u2019s lead pipeline candidate is MET-097i, a weekly and monthly injectable GLP-1 RA about to begin phase III development. It is also developing an ultra-long-acting amylin analog, MET-233i, and an oral GLP-1 RA candidate\u00a0in phase I. Additional preclinical, nutrient-stimulated hormone therapeutics were also added to Pfizer\u2019s pipeline.<\/p>\n

Pfizer also signed a drug pricing agreement with the Trump administration in September. It has offered to cut prescription drug prices and boost domestic investments in exchange for a three-year exemption from tariffs on pharmaceutical imports.<\/p>\n

However, Pfizer too faces its share of challenges. It is seeing a softness in sales of its COVID products, Comirnaty and Paxlovid, due to lower vaccination rates and COVID infection rates.<\/p>\n

Pfizer also expects a significant impact from the loss of patent exclusivity in the 2026-2030 period, as several of its key products, including Eliquis, Vyndaqel, Ibrance, Xeljanz and Xtandi, will face patent expirations. The company expects an unfavorable impact of approximately $1 billion from the Medicare Part D redesign under the Inflation Reduction Act (IRA), which took effect in the first quarter of 2025 and is hurting Pfizer\u2019s revenues. Higher-priced drugs, including Eliquis, Vyndaqel, Ibrance, Xtandi and Xeljanz, are expected to be most affected by the IRA.<\/p>\n

How Do Estimates Compare for NVO & PFE?<\/p>\n

The Zacks Consensus Estimate for Novo Nordisk\u2019s 2025 sales and earnings per share (EPS) implies a year-over-year increase of around 14% and 9%, respectively. EPS estimates for both 2025 and 2026 have been trending downward over the past 60 days.<\/p>\n

NVO Estimate Movement<\/p>\n

\"ZacksImage Source: Zacks Investment Research<\/p>\n

The Zacks Consensus Estimate for Pfizer\u2019s 2025 sales and EPS implies a year-over-year decrease of 1.1% and an increase of 1%, respectively. PFE\u2019s EPS estimates for both 2025 and 2026 have also been trending downward over the past 60 days.<\/p>\n

PFE Estimate Movement<\/p>\n

\"ZacksImage Source: Zacks Investment Research<\/p>\n

Price Performance and Valuation of NVO & PFE<\/p>\n

Year to date, shares of NVO have plummeted 43.4%, while those of PFE have lost 3.1%. In comparison, the\u00a0industry<\/a>\u00a0has gained 19%, as seen in the chart below.<\/p>\n

\"ZacksImage Source: Zacks Investment Research<\/p>\n

From a valuation standpoint, Novo Nordisk is more expensive than Pfizer, going by the price\/earnings ratio. NVO\u2019s shares currently trade at 13.36 times forward earnings, higher than 8.2 for PFE.<\/p>\n

\"ZacksImage Source: Zacks Investment Research<\/p>\n

NVO vs. PFE: Which Stock Holds the Edge?<\/p>\n

Novo Nordisk and Pfizer carry a Zacks Rank #3 (Hold) each, which makes choosing one stock a difficult task. You can see\u00a0the complete list of today\u2019s Zacks #1 Rank (Strong Buy) stocks here<\/a>.<\/p>\n

However, NVO has recently faced serious market turmoil, navigating several near-term challenges, including intensifying competition from Eli Lilly, battling compounded semaglutide alternatives in the market, guidance cuts and leadership transitions. These factors have weighed on investor sentiment, resulting in a steep decline in share value over the past year.<\/p>\n

In contrast, despite stock volatility, Pfizer offers an attractive near-term investment case as post-COVID volatility subsides and core revenues strengthen. Its oncology franchise, bolstered by Seagen, continues to grow, while new and acquired products add momentum. The $10 billion Metsera deal also returns Pfizer to the fast-growing obesity market with promising incretin and amylin programs. With $7.7 billion in planned cost savings by 2027, a solid late-stage pipeline and a compelling ~7% dividend yield, Pfizer stands out as a cheaper, more stable option than NVO for investors seeking EPS growth and steady performance.<\/p>\n

\tQuantum Computing Stocks Set To Soar<\/p>\n

\n\tArtificial intelligence has already reshaped the investment landscape, and its convergence with quantum computing could lead to the most significant wealth-building opportunities of our time.<\/p>\n

\n\tToday, you have a chance to position your portfolio at the forefront of this technological revolution. In our urgent special report, Beyond AI: The Quantum Leap in Computing Power, you’ll discover the little-known stocks we believe will win the quantum computing race and deliver massive gains to early investors.<\/p>\n

Access the Report Free Now >><\/a><\/p>\n

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report<\/a><\/p>\n

Pfizer Inc. (PFE) : Free Stock Analysis Report<\/a><\/p>\n

Novo Nordisk A\/S (NVO) : Free Stock Analysis Report<\/a><\/p>\n

Eli Lilly and Company (LLY) : Free Stock Analysis Report<\/a><\/p>\n

This article originally published on Zacks Investment Research (zacks.com).<\/a><\/p>\n

Zacks Investment Research<\/a><\/p>\n

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.<\/p>\n","protected":false},"excerpt":{"rendered":"Novo Nordisk\u00a0NVO and Pfizer PFE are pharmaceutical giants based in Denmark and the United States, respectively, with strong…\n","protected":false},"author":2,"featured_media":84544,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[34],"tags":[64,63,137,500],"class_list":{"0":"post-313876","1":"post","2":"type-post","3":"status-publish","4":"format-standard","5":"has-post-thumbnail","7":"category-healthcare","8":"tag-au","9":"tag-australia","10":"tag-health","11":"tag-healthcare"},"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts\/313876","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/comments?post=313876"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts\/313876\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/media\/84544"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/media?parent=313876"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/categories?post=313876"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/tags?post=313876"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}